SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-040057
Filing Date
2023-11-09
Accepted
2023-11-09 16:10:32
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38329
2 ex99-1.htm EX-99.1 223176
3 ex99-1_001.jpg GRAPHIC 15482
  Complete submission text file 0001493152-23-040057.txt   475835

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lctx-20231109.xsd EX-101.SCH 3024
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lctx-20231109_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lctx-20231109_pre.xml EX-101.PRE 22365
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3302
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 231392474
SIC: 2836 Biological Products, (No Diagnostic Substances)